Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma.

被引：0
|
作者：
Oliver, T
Dieckmann, KP
Steiner, H
Skoneczna, I
机构：
[1] QMUL, St Barts & London Sch Med, London, England
[2] Albertenan Hosp, Hamburg, Germany
[3] Med Univ Innsbruck, Innsbruck, Austria
[4] Inst Oncol, Warsaw, Poland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：395S / 395S
页数：1
相关论文
共 50 条
  • [31] Analysis of highly excited 'hot' bands in the SO2 molecule: v2+3v3-v2 and 2v1+v2+v3-v2
    Ulenikov, O. N.
    Bekhtereva, E. S.
    Gromova, O. V.
    Alanko, S.
    Horneman, V-M
    Leroy, C.
    MOLECULAR PHYSICS, 2010, 108 (10) : 1253 - 1261
  • [32] PHASE-DIAGRAM OF V1-XALXO2 SYSTEM
    DRILLON, M
    VILLENEUVE, G
    MATERIALS RESEARCH BULLETIN, 1974, 9 (09) : 1199 - 1208
  • [33] IMPROVED RISK ASSESSMENT BY MOLECULAR GENETIC PROFILING IN EARLY STAGE ENDOMETRIAL CANCER: A POOLED PORTEC-1 AND-2 ANALYSIS
    Stelloo, E.
    Nout, R. A.
    Osse, E. M.
    Jurgenliemk-Schulz, I. M.
    Jobsen, J. J.
    Lutgens, L. C.
    van der Steen-Banasik, E. M.
    Nijman, H. W.
    Putter, H.
    Bosse, T.
    Creutzberg, C. L.
    Smit, V. T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 11 - 12
  • [34] Is adjuvant radiotherapy necessary for FIGO stage 1a grade 2 endometrial endometrioid adenocarcinoma?
    Inan, Abdurrahman Hamdi
    Ersoy, Gulcin Sahin
    Yildinm, Yusuf
    Gurbuz, Tutku
    Kebapcilar, Ayse Gul
    Hanhan, Merih
    JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION, 2015, 16 (03) : 153 - 157
  • [35] Does Adjuvant Therapy Make a Difference for Stage 1A Type 2 Endometrial Cancer?
    Gebhardt, B. J.
    Horne, Z. D.
    Dohopolski, M. J.
    Kelley, J. L.
    Sukumvanich, P.
    Edwards, R. P.
    Comerci, J. T.
    Olawaiye, A. B.
    Courtney-Brooks, M.
    Boisen, M. M.
    Berger, J. L.
    Beriwal, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S229 - S229
  • [36] PHASE-TRANSITION M1-]T IN V1-XGAXO2
    BRUCKNER, W
    BRUCKNER, HP
    GERLACH, U
    THUSS, B
    FORSTERLING, G
    PHYSICA STATUS SOLIDI A-APPLIED RESEARCH, 1976, 38 (01): : K13 - K16
  • [37] First high resolution analysis of the 2v1, 2v3, and v1 + v3 bands of S18O2
    Ulenikov, O. N.
    Bekhtereva, E. S.
    Gromova, O. V.
    Zamotaeva, V. A.
    Sklyarova, E. A.
    Sydow, C.
    Maul, C.
    Bauerecker, S.
    JOURNAL OF QUANTITATIVE SPECTROSCOPY & RADIATIVE TRANSFER, 2016, 185 : 12 - 21
  • [38] Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events
    Gazzah, Anas
    Tabernero, Josep
    Italiano, Antoine
    Cousin, Sophie
    Barlesi, Fabrice
    Lena, Herve
    Bedard, Philippe L.
    Ryu, Min-Hee
    Sung, Kyung Rim
    Cho, Byoung Chul
    Calvo, Emiliano
    Yoruk, Semra
    Chadjaa, Mustapha
    Masson, Nina
    Fagniez, Nathalie
    Balaguer, Oscar
    Brosa, Helena
    Gabison, Eric E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
    Hong, David S.
    DuBois, Steven G.
    Kummar, Shivaani
    Farago, Anna F.
    Albert, Catherine M.
    Rohrberg, Kristoffer S.
    van Tilburg, Cornelis M.
    Nagasubramanian, Ramamoorthy
    Berlin, Jordan D.
    Federman, Noah
    Mascarenhas, Leo
    Geoerger, Birgit
    Dowlati, Afshin
    Pappo, Alberto S.
    Bielack, Stefan
    Doz, Francois
    McDermott, Ray
    Patel, Jyoti D.
    Schilder, Russell J.
    Tahara, Makoto
    Pfister, Stefan M.
    Witt, Olaf
    Ladanyi, Marc
    Rudzinski, Erin R.
    Nanda, Shivani
    Childs, Barrett H.
    Laetsch, Theodore W.
    Hyman, David M.
    Drilon, Alexander
    LANCET ONCOLOGY, 2020, 21 (04): : 531 - 540
  • [40] Phase 1/2 Trial of Cirmtuzumab and Ibrutinib: Planned Analysis of Phase 1 CLL Cohorts
    O'Brien, Susan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (07) : 18 - 19
12345